CIK 0001035354 · Non-accelerated filer<br>Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 841368850
- Phone
- 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +1,422,222 | $1.35 | $1.9M | 1,989,551 |
| 2021-05-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +592,592 | $1.35 | $800K | 616,592 |
| 2021-05-13 | Nussbaum Ran Director | Purchase | +1,280,624 | $1.35 | $1.7M | 1,791,470 |
| 2021-05-13 | Nussbaum Ran Director | Purchase | +2,630,487 | $1.35 | $3.6M | 3,679,797 |
| 2021-05-13 | Nussbaum Ran Director | Purchase | +1,422,222 | $1.35 | $1.9M | 1,989,551 |
| 2021-05-13 | Nussbaum Ran Director | Purchase | +592,592 | $1.35 | $800K | 616,592 |
| 2021-05-13 | Kariv Tomer Director | Purchase | +1,280,624 | $1.35 | $1.7M | 1,791,470 |
| 2021-05-13 | Kariv Tomer Director | Purchase | +2,630,487 | $1.35 | $3.6M | 3,679,797 |
| 2021-05-13 | Kariv Tomer Director | Purchase | +1,422,222 | $1.35 | $1.9M | 1,989,551 |
| 2021-05-13 | Kariv Tomer Director | Purchase | +592,592 | $1.35 | $800K | 616,592 |
| 2021-04-30 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Option exercise | +1,562 | 27,639 | ||
| 2021-04-30 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Shares withheld for taxes | −459 | $2.18 | $1K | 27,180 |
| 2021-04-30 | Belloff Neil S. COO, GENERAL COUNSEL &CORP SEC | Option exercise · Restricted Stock Units | −1,562 | 10,938 | ||
| 2021-04-20 | Geffken Daniel E. CHIEF FINANCIAL OFFICER | Grant or award · Non-Qualified Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-04-01 | PAREKH RAJESH B Director | Grant or award | +87,031 | 87,031 | ||
| 2021-04-01 | PAREKH RAJESH B Director | Grant or award | +2,445,239 | 2,445,239 | ||
| 2021-04-01 | PAREKH RAJESH B Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2021-04-01 | Walts Alan Edmund Director | Grant or award · Restricted Stock Units | +37,695 | 37,695 | ||
| 2021-04-01 | Walts Alan Edmund Director | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2021-04-01 | MODUR VIJAY HEAD OF R&D | Grant or award · Restricted Stock Units | +174,643 | 174,643 |
Page 6 of 11 · 206 trades